VYNE Therapeutics (VYNE) Capital Expenditures (2017 - 2021)

VYNE Therapeutics' Capital Expenditures history runs 5 years deep, the most recent figure standing at $376000.0 for Q4 2021.

• Quarterly Capital Expenditures changed N/A year-over-year to $376000.0 in Q4 2021, while the trailing twelve-month figure through Sep 2022 was $376000.0 (up 130.9% YoY) and the FY2024 annual result came in at $117000.0, changed N/A from the prior year.
• Capital Expenditures was $376000.0 for Q4 2021 at VYNE Therapeutics, up from -$341000.0 in the prior quarter.
• Across five years, Capital Expenditures topped out at $934000.0 in Q4 2019 and bottomed at -$472000.0 in Q2 2021.
• A 5-year average of $55400.0 and a median of $71000.0 in 2020 frame the typical range for Capital Expenditures.
• Annual changes were most pronounced in 2018 — Capital Expenditures jumped 228.79% — and 2021, when it sank 1061.9%.
• VYNE Therapeutics' Capital Expenditures stood at -$66000.0 in 2017, then jumped by 780.3% to $449000.0 in 2018, then surged by 108.02% to $934000.0 in 2019, then slumped by 92.4% to $71000.0 in 2020, then jumped by 429.58% to $376000.0 in 2021.
• Business Quant data shows VYNE's Capital Expenditures at $376000.0 in Q4 2021, -$341000.0 in Q3 2021, and -$472000.0 in Q2 2021.